1887
Rapid communication Open Access
Like 0

Abstract

By employing a common protocol and data from electronic health registries in Denmark, Navarre (Spain), Norway and Portugal, we estimated vaccine effectiveness (VE) against hospitalisation due to COVID-19 in individuals aged ≥ 65 years old, without previous documented infection, between October 2021 and March 2022. VE was higher in 65–79-year-olds compared with ≥ 80-year-olds and in those who received a booster compared with those who were primary vaccinated. VE remained high (ca 80%) between ≥ 12 and < 24 weeks after the first booster administration, and after Omicron became dominant.

Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2022.27.30.2200551
2022-07-28
2022-08-10
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2022.27.30.2200551
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/27/30/eurosurv-27-30-1.html?itemId=/content/10.2807/1560-7917.ES.2022.27.30.2200551&mimeType=html&fmt=ahah

References

  1. European Centre for Disease Prevention and Control (ECDC). Overview of the implementation of COVID-19 vaccination strategies and deployment plans in the EU/EEA. Stockholm: ECDC; 21 Apr 2022. [Accessed 13 Jun 2022]. Available from: https://www.ecdc.europa.eu/en/publications-data/overview-implementation-covid-19-vaccination-strategies-and-deployment-plans
  2. European Centre for Disease Prevention and Control (ECDC). Weekly epidemiological update: Omicron variant of concern (VOC) – week 2 (data as of 20 January 2022) EU/EEA. Stockholm: ECDC; 21 Jan 2022. [Accessed 16 Jun 2022]. Available from: https://www.ecdc.europa.eu/en/news-events/weekly-epidemiological-update-omicron-variant-concern-voc-week-2-data-20-january-2022
  3. Chapter 10: Analysing data and undertaking meta-analyses. Cochrane Training. [Accessed 13 Jun 2022]. Available from: https://training.cochrane.org/handbook/archive/v6.2/chapter-10#section-10-3
  4. European Centre for Disease Prevention and Control (ECDC). Engagement of ECDC in projects funded through the Horizon 2020 call for Pan-European COVID-19 cohorts. Stockholm: ECDC; 9 Jun 2020. Available from: https://www.ecdc.europa.eu/en/news-events/engagement-ECDC-projects-funded-through-call-for-Pan-European-COVID-19-cohorts
  5. Goldberg Y, Mandel M, Bar-On YM, Bodenheimer O, Freedman L, Haas EJ, et al. Waning Immunity after the BNT162b2 Vaccine in Israel. N Engl J Med. 2021;385(24):e85.  https://doi.org/10.1056/NEJMoa2114228  PMID: 34706170 
  6. Fabiani M, Puopolo M, Morciano C, Spuri M, Spila Alegiani S, Filia A, et al. Effectiveness of mRNA vaccines and waning of protection against SARS-CoV-2 infection and severe covid-19 during predominant circulation of the delta variant in Italy: retrospective cohort study. BMJ. 2022;376:e069052.  https://doi.org/10.1136/bmj-2021-069052  PMID: 35144968 
  7. Nanishi E, Levy O, Ozonoff A. Waning effectiveness of SARS-CoV-2 mRNA vaccines in older adults: a rapid review. Hum Vaccin Immunother. 2022;18(5):2045857.  https://doi.org/10.1080/21645515.2022.2045857  PMID: 35240940 
  8. Andrews N, Tessier E, Stowe J, Gower C, Kirsebom F, Simmons R, et al. Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines. N Engl J Med. 2022;386(4):340-50.  https://doi.org/10.1056/NEJMoa2115481  PMID: 35021002 
  9. Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, et al. Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. N Engl J Med. 2022;386(16):1532-46.  https://doi.org/10.1056/NEJMoa2119451  PMID: 35249272 
  10. Barda N, Dagan N, Cohen C, Hernán MA, Lipsitch M, Kohane IS, et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. Lancet. 2021;398(10316):2093-100.  https://doi.org/10.1016/S0140-6736(21)02249-2  PMID: 34756184 
  11. Arbel R, Hammerman A, Sergienko R, Friger M, Peretz A, Netzer D, et al. BNT162b2 Vaccine Booster and Mortality Due to Covid-19. N Engl J Med. 2021;385(26):2413-20.  https://doi.org/10.1056/NEJMoa2115624  PMID: 34879190 
  12. Abu-Raddad LJ, Chemaitelly H, Ayoub HH, AlMukdad S, Yassine HM, Al-Khatib HA, et al. Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar. N Engl J Med. 2022;386(19):1804-16.  https://doi.org/10.1056/NEJMoa2200797  PMID: 35263534 
  13. Ferdinands JM, Rao S, Dixon BE, Mitchell PK, DeSilva MB, Irving SA, et al. Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022;71(7):255-63.  https://doi.org/10.15585/mmwr.mm7107e2  PMID: 35176007 
  14. Patalon T, Saciuk Y, Peretz A, Perez G, Lurie Y, Maor Y, et al. Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine. Nat Commun. 2022;13(1):3203.  https://doi.org/10.1038/s41467-022-30884-6  PMID: 35680872 
/content/10.2807/1560-7917.ES.2022.27.30.2200551
Loading

Data & Media loading...

Supplementary data

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error